Q1 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2021-04-27 | ||||||
REV |
Q4 2020 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2021-03-19 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
Ticker | Company | Price | Change | Chg % | Mkt Cap | |
---|---|---|---|---|---|---|
INBX | Inhibrx | 26.39 | -0.17 | -0.64% | 995.2M |
You can purchase shares of Inhibrx (NASDAQ: INBX) through any online brokerage.
Other companies in Inhibrx’s space includes: Avidity Biosciences (NASDAQ:RNA), Trillium Therapeutics (NASDAQ:TRIL) and TCR2 Therapeutics (NASDAQ:TCRR).
The latest price target for Inhibrx (NASDAQ: INBX) was reported by Jefferies on 2020-09-14. The analyst firm set a price target for 30.00 expecting INBX to rise to within 12 months (a possible 13.68% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Inhibrx (NASDAQ: INBX) is $26.39 last updated Fri Mar 05 2021 21:00:01 GMT+0000 (Coordinated Universal Time).
There are no upcoming dividends for Inhibrx.
There is no upcoming split for Inhibrx.